

<sup>\*</sup> Generic Epclusa is not indicated for pediatric patients who should be referred to ID/GI/hepatologist.


This clinical guideline was prepared by the Office of Public Health on behalf of the Louisiana Test and Treat Panel. It does not reflect official Louisiana Medicaid reimbursement policy and should not be construed to limit or guarantee Medicaid reimbursement of services.

<sup>\*</sup> Prior DAA use applies to exclusively oral regimens only.

<sup>\*</sup> HIV+ patients may be referred to ID or experienced HCV provider.



HCV confirmed with HCV viral load




- APRI > 2
- Fib-4 > 3.25
- Fibrosure  $\geq 0.75$

• HAV vaccination if Hep A Ab-

• HBV vaccination if Hep Bs Ab-





## POST TREATMENT ALGORITHM

**All HCV patients** 

Stage 0,1,2,3 fibrosis (pre-treatment staging) Stage 4 fibrosis (cirrhosis)

SVR12 and hepatic function @ 12 weeks after treatment

SVR12 and hepatic function @ 12 weeks after treatment

If HCV RNA is negative and
liver tests normal no additional followup needed

Refer to GI/Hepatology

If HCV RNA positive and/or liver tests abnormal refer to GI/hepatologist

SVR12= HCV viral load negative 12 weeks after treatment; patient is considered cured.